Abstract: Objective To investigate the relationship between the rs10759225 polymorphism of the RAD23B gene and clinical outcomes of platinum-based chemotherapy　as　first-line　treatment in patients with advanced non-small cell lung cancer（NSCLC）. Methods The clinical data and peripheral blood samples of 150 NSCLC patients receiving first-line treatment with platinum-based combination regimen were retrospectively analyzed.　The polymorphism of rs10759225 was genotyped by improved multiple ligase detection reaction（iMLDR） technology. Results The overall response rate（ORR） was 27.8%（43/150） of all group.Compared with G/G genotype carriers，A allele（included G/A genotype and A/A genotype） carriers had markedly higher response rate （OR_adjusted =1.780，95%CI：1.110-2.884，P=0.042）.The median progression-free　survival（mPFS） of all patients was 5.6 months，and there was no significance of mPFS among difference genotype groups（P>0.05）.　Compared with G/G genotype （as a reference），A/A genotype increased the risk of grade Ⅲ/Ⅳ of leukopenia （OR_adjusted=0.468，95%CI：0.204-0.711，P=0.008），and an allele was each associated with grade Ⅲ/Ⅳ of neutropenia （OR_adjusted=0.502，95%CI：0.155-0.887，P=0.022） and grade ≥Ⅰ of thrombocytopenia（OR_adjusted=0.494，95%CI：0.101-0.833，P=0.047），respectively.The risk of grade Ⅱ/Ⅲ anemia was significantly higher in patients with G/A genotype compared with G/G genotype carriers（OR_校正=0.504，95%CI：0.213~0.890，P=0.047）.　Conclusions RAD23B gene rs10759225 polymorphism is associated with response rate and hematological toxicity of NSCLC patients treated with platinum-based chemotherapy，but there is no relationship between the polymorphism and the PFS of patients.Compared with G/G genotype carriers，A allele carriers may have better efficacy，and，as well as have a higher risk of myelosuppression.

Key words: Non-small cell lung cancer, Chemotherapy, Platinum, RAD23B gene, Single nucleotide polymorphisms, Genotye